ReviewDigestive diseases and sciences2026
Animal Models of Slow-Transit Constipation: Current Progress, Limitations, and Future Perspectives.
Review in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSlow-transit constipation (STC) is a subtype of chronic constipation characterized by delayed colonic transit without obstructive defecation. Because in vivo human experimentation is constrained, animal models remain the primary tool for probing STC pathogenesis and testing therapies, yet no unified framework exists for judging howwell current models reproduce human disease. This review systematically appraises the reported STC animal models against a single validity framework and identifies design criteria for the next generation of models.
methodsWe reviewed pharmacological agent-induced models (loperamide, diphenoxylate, alosetron, morphine, atropine), a physical stimulus model (ice-water gavage), surgical models (rectal distension, partial outlet obstruction, chemical ablation of the enteric plexus), and a naturally occurring inbred strain (the CFP/Yit mouse), and appraised each using the Face-Construct-Predictive validity framework.
resultsExisting models show substantial gaps in face validity (drug-withdrawal-dependent, self-limiting constipation rather than chronic progressive dysmotility), construct validity (few reproduce enteric glial cell loss, enteric neuronde generation, interstitial cell of Cajal depletion, and inflammatory infiltration), and predictive validity (induction agents confound therapeutic readouts). Advances in enteric glial biology, microbiota-short-chain fatty acid-motility signalling, single-cell transcriptomics of enteric glia, and genetic susceptibility point toward transgenic, pelvic-nerve-intervention, selective enteric glial ablation, and organoid-enteric nervous system co-culture designs, with sex-stratified evaluation and systematic clinical translation studies.
conclusionThe Face-Construct-Predictive framework exposes the translational shortfall of current STC animal models and defines concrete design criteria for clinically relevant successors, guiding model selection and prioritizing future research.
Indexed as
Identifiers
42875723What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.